Human Immunodeficiency Virus Therapeutics Market Expected To Grow At 5.4% CAGR Through 2030: What Businesses Need To Know

Human Immunodeficiency Virus Therapeutics Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Human Immunodeficiency Virus Therapeutics Market Forecast: What Value Will The Market Reach By 2030?

The human immunodeficiency virus therapeutics market size has exhibited strong growth in recent years. It is anticipated to expand from $14.9 billion in 2025 to $15.73 billion in 2026, registering a compound annual growth rate (CAGR) of 5.6%. The historical growth can be ascribed to several factors, including the global burden of hiv infections, the widespread adoption of antiretroviral therapy, government-funded hiv treatment programs, the increasing availability of generic hiv drugs, and improved survival rates among hiv patients.

The human immunodeficiency virus therapeutics market is projected to experience substantial expansion in the upcoming years. This market is anticipated to reach a value of $19.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This projected growth stems from several factors, including the increasing demand for extended-duration HIV treatments, a heightened emphasis on individualized HIV treatment plans, broader availability of HIV care in developing nations, increased funding for advanced antiretroviral medications, and a greater focus on continuous HIV disease management throughout a patient’s life. Key trends foreseen for this period encompass the wider embrace of combination antiretroviral therapies, a noticeable move towards long-acting injectable HIV treatments, a heightened commitment to achieving early and consistent viral suppression, the increased availability of generic antiretroviral drugs, and an augmented focus on ensuring treatment adherence alongside simplified regimens.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=17129094&type=smp&name=Human%20Immunodeficiency%20Virus%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Human Immunodeficiency Virus Therapeutics Market Expansion Drivers: What’s Shaping Future Growth?

The increasing occurrence of unprotected sexual acts is anticipated to drive the expansion of the human immunodeficiency virus therapeutics market in the future. These practices involve sexual encounters lacking barrier protection, thereby elevating the likelihood of sexually transmitted infections (STIs) and unplanned pregnancies. Inadequate comprehensive sex education contributes to insufficient knowledge regarding safe practices, thereby fostering risky conduct among young individuals. Therapeutics for human immunodeficiency virus aid in mitigating the danger of HIV transmission resulting from unprotected sexual activities by bringing viral load down to undetectable levels, thus inhibiting the continued spread of the infection. As an illustration, data from November 2024, provided by the Centers for Disease Control and Prevention, a government agency in the US, revealed that a 2023 survey of U.S. high school students showed 32% had engaged in sexual intercourse at least once, and 48% reported not using a condom during their most recent sexual encounter. Consequently, the rising incidence of unprotected sexual practices is fueling the expansion of the human immunodeficiency virus therapeutics market.

Human Immunodeficiency Virus Therapeutics Market Breakdown By Product Type And Application

The human immunodeficiency virus therapeutics market covered in this report is segmented –

1) By Drug Type: Branded Drugs, Generic Drugs

2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

3) By End-user: Hospitals And Clinics, Specialty Centers

Subsegments:

1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista

2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir

Human Immunodeficiency Virus Therapeutics Market Strategic Trends: What Defines The Next Growth Phase?

Major companies operating in the Human Immunodeficiency Virus Therapeutics market are focusing on developing long-acting, highly effective prevention and treatment options, expanding access through supportive reimbursement programs, and advancing innovative clinical strategies to improve adherence and reduce new HIV infections. For instance, in June 2025, Gilead Sciences, a US-based healthcare company, received FDA approval for Yeztugo (lenacapavir), the first and only twice-yearly injectable PrEP option, marking a major advancement in HIV prevention. Backed by Phase 3 PURPOSE 1 and PURPOSE 2 data, the drug showed exceptional efficacy, with =99.9% of participants remaining HIV-negative. The long-acting injection aims to overcome barriers such as adherence challenges, stigma, and low awareness that limit current PrEP use. Yeztugo’s approval offers a promising tool to help reduce new HIV infections across diverse populations. Gilead is also implementing broad access measures, including insurance partnerships, co-pay support for eligible patients, and free access for uninsured individuals through assistance programs.

Human Immunodeficiency Virus Therapeutics Market Company Landscape And Competitive Strategy

Major companies operating in the human immunodeficiency virus therapeutics market are Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., F Hoffmann La Roche Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Hetero Labs Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr Reddy’s Laboratories Ltd., Mylan N.V.

View The Full Human Immunodeficiency Virus Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/human-immunodeficiency-virus-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Human Immunodeficiency Virus Therapeutics Market Largest Region: Which Geography Holds The Biggest Share?

North America was the largest region in the human immunodeficiency virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model